Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01101334 · ClinicalTrials.gov registry record · Phase 2
Study of Erlotinib With or Without Investigational Drug (CS-7017) in Subjects With Advanced Non-small Cell Lung Cancer
A Phase 2 study, sponsored by Daiichi Sankyo.
- Completed
- Registry status
- Phase 2
- Development phase
- 90
- Enrollment target
NCT01101334 is a Phase 2 study that has completed, run by Daiichi Sankyo. The registered enrollment target is 90 participants.
The verdict
NCT01101334, a Phase 2 study, has completed, sponsored by Daiichi Sankyo.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 90 participants
- Enrollment target
Study Summary
This is a Phase 2 and open-label (subject will know the treatment he or she is receiving) study. The subject will receive either Erlotinib alone or Erlotinib + CS-7017 in this study. The study will determine what effect adding CS-7017 to Erlotinib has on safety and length of survival in subjects with advanced non-small cell lung cancer who failed the first treatment.
Interventions
- DRUG erlotinib
- DRUG CS-7017
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2010-03 |
| Est. Completion | 2013-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01101334
The ClinicalTrials.gov registry entry for NCT01101334 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 90 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Daiichi Sankyo, which has 236 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which erlotinib is the first listed.
NCT01101334 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01101334 about?
NCT01101334 is a clinical study titled "Study of Erlotinib With or Without Investigational Drug (CS-7017) in Subjects With Advanced Non-small Cell Lung Cancer". This is a Phase 2 and open-label (subject will know the treatment he or she is receiving) study. The subject will receive either Erlotinib alone or Erlotinib + CS-7017 in this study. The study will determine what effect adding CS-7017 to Erlotinib has on safety and length of survival in subjects wi...
What is the current status of trial NCT01101334?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 90 participants. The study started on 2010-03. Estimated completion is 2013-04.
What interventions are being tested in trial NCT01101334?
The interventions under investigation include: erlotinib (DRUG), CS-7017 (DRUG).
Who is sponsoring clinical trial NCT01101334?
This trial is sponsored by Daiichi Sankyo, which has 236 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.